Marc Botnick, MD, a board-certified radiation oncologist with more than 20 years of experience managing all cancer types, has been named regional medical director for Radiation Oncology at Cedars-Sinai Cancer. His primary clinical practice site will be at Cedars-Sinai Tarzana Radiation Oncology, but he will work closely with physicians throughout the enterprise.
Holly Hammond faced one of the toughest-imaginable breast cancer scenarios. Her cancer was already advanced and had spread to her liver and lymph nodes when she discovered a tumor on her right breast. The tumor was negative for all of the markers that respond to targeted therapies for cancer treatment. She was also positive for the genes that mark her as especially prone to breast cancer.
Howard Sandler, MD, chair of the Department of Radiation Oncology at Cedars-Sinai Cancer, has been named president-elect of the American Society for Radiation Oncology (ASTRO). Sandler will begin his term as president-elect in October, followed by single-year terms as president, chair and then immediate past chair of the ASTRO Board.
A Roundup of the Latest Medical Discoveries and Faculty News at Cedars-Sinai
Experts from Cedars-Sinai Cancer are available to comment on the American Association for Cancer Research (AACR) Cancer Disparities Progress Report 2022, which will be released Wednesday, June 8, in a virtual congressional briefing. The report highlights the need to increase diversity in clinical trials and the cancer workforce, and it provides policy recommendations for addressing cancer disparities—all areas Cedars-Sinai Cancer is working to address.
Recently, Michael Wulfe, who is 61 and lives in West Hollywood, was on the phone with his sister, Stephanie Wulfe, in Dallas. They talk at least once a day, but that day, something wasn’t right. “I was talking, and then I didn’t have the words,” Wulfe said. “My sister immediately said, ‘Call Cedars-Sinai!’”
Results of a Phase II clinical trial led by Cedars-Sinai Cancer investigators indicate that an immunotherapy drug combination could extend the lives of those diagnosed with advanced non-small cell lung cancer, one of the most common forms of lung cancer. The research was presented today during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, with simultaneous publication in the peer-reviewed Journal of Clinical Oncology.
Patients newly diagnosed with cancer typically focus on one question, eclipsing all others: “What is my prognosis?”
Experts from Cedars-Sinai Cancer, ranked among the top 10 in the nation for cancer care, will present novel research and clinical advances throughout the 2022 annual meeting of the American Society of Clinical Oncology (ASCO), taking place in person and virtually June 3-7 in Chicago.
Practice-changing research from Cedars-Sinai Cancer shows that a combination of androgen deprivation therapy—a commonly used hormone injection—plus pelvic lymph node radiation, kept nearly 90% of clinical trial patients’ prostate cancer at bay for five years. The findings were published in the peer-reviewed journal The Lancet.
Studies have shown that the way LGBTQ+ patients are screened, diagnosed and treated for cancer may put them at a significant disadvantage compared to cisgender heterosexual patients.
This tipsheet highlights the latest medical discoveries and faculty news at Cedars-Sinai. Links to full news releases are included with each item.
A hallmark of cancer is its ability to replicate, a process commonly driven by the reactivation of the telomerase enzyme complex, which helps prevent the aging and death of healthy cells and keeps stem cells in bone marrow and the intestines from producing normal cells in those organs. When telomerase is activated in cancer cells, it helps them survive and duplicate in the body.
Cedars-Sinai Cancer and Tempus, a leader in artificial intelligence and precision medicine, are harnessing the power of big data and AI to design personalized cancer treatment options by creating virtual replicas of patients’ DNA, RNA, protein and other information to help identify the most effective approach to each individual’s disease.
Two internationally prominent cancer experts from Cedars-Sinai and USC will train a new generation of investigators to propel scientific advances in cancer through a novel grant from the U.S. Department of Defense.
Researchers have discovered a new way to transform the tissues surrounding prostate tumors to help the body’s immune cells fight the cancer. The discovery, made in human and mouse cells and in laboratory mice, could lead to improvements in immunotherapy treatments for prostate cancer, the second most common cancer in men in the U.S.
Internationally prominent gynecologic oncologist Kenneth H. Kim, MD, recently was selected to direct the Division of Gynecologic Oncology at Cedars-Sinai Cancer. He also serves as chair of the cancer center’s Committee for Oversight of Training and Education.
A new approach to cancer therapy shows potential to transform the commonly used chemotherapy drug gemcitabine into a drug that kills cancer cells in a specialized way, activating immune cells to fight the cancer, according to a study led by Cedars-Sinai Cancer investigators.
Internationally recognized hematologist John P. Chute, MD, has been selected to direct the Division of Hematology and Cellular Therapy in the Department of Medicine at Cedars-Sinai Cancer. The physician-scientist also will serve as director of the Center for Myelodysplastic Diseases Research and associate director of the Board of Governors Regenerative Medicine Institute in the Department of Biomedical Sciences.